Increased survivin expression is a negative prognostic marker in many tumours, including ovarian cancer. We show here that ovarian carcinoma cells upregulate survivin transcription in response to increased expression of the proapoptotic protein procaspase 3. We have utilized this observation in a combination gene therapy strategy using adenoviral constructs expressing the dominant-negative mutant survivin T34A (Ad Survivin T34A) and procaspase 3 (Ad Caspase 3) in ovarian carcinoma cell lines. Transfection of ovarian carcinoma cells with Ad Survivin T34A induces apoptosis via a caspase 9-mediated pathway that is not affected by cell cycle block prior to G2/M. Ad Survivin T34A-induced apoptosis can be significantly enhanced by cotransfection with Ad Caspase 3, and the combination of Ad Survivin T34A and Ad Caspase 3 leads to a significant increase in survival in a murine intraperitoneal ovarian carcinoma model with some long-term survivors. This suggests that inhibiting endogenous survivin activity while also delivering high levels of procaspase 3 allow proteolytic cleavage and activation of the terminal caspase cascade leading to tumour cell death.
Introduction
Members of the inhibitor of apoptosis protein (IAP) family, which include c-IAP-1, c-IAP-2 and XIAP, are characterized by the presence of one or more baculovirus inhibitor of apoptosis repeat (BIR) domains and are known to interact with caspases via these domains to prevent caspase activation (Liston et al., 1996; Deveraux et al., 1997; Takahashi et al., 1998) . XIAP, the most extensively investigated IAP, contains three BIR domains; the BIR2 and the amino acids immediately Nterminal to BIR2 interact with caspase-3, while the BIR3 domain binds caspase-9 thereby preventing activation of the intrinsic apoptotic cascade (Takahashi et al., 1998; . Survivin is frequently included as an IAP family member because of the presence of a single BIR3 domain, although there remains considerable debate as to the exact function of this domain. Expression of survivin, like XIAP, has been reported to be substantially increased in tumours and is a marker of negative prognostic significance (Asanuma et al., 2000; Sarela et al., 2000; Yoshida et al., 2001) . Survivin is expressed at significantly higher levels in clear cell adenocarcinomas of the ovary as compared to normal ovary and these tumours are more likely to be resistant to platinum-based chemotherapies and have a poor prognosis (Yoshida et al., 2001) .
Although survivin expression appears to have an inhibitory effect on apoptosis in many cancers, it is still not completely clear how this is mediated Tamm et al., 1998) . Survivin appears to be closely linked to the mitotic process. In normal tissues, it is only expressed at detectable levels at G2/M in the cell cycle, and, at this point, survivin protein migrates to the microtubules in a process similar to chromosomal passenger proteins, notably INCENP (Skoufias et al., 2000; Speliotes et al., 2000; Suzuki et al., 2000; Uren et al., 2000; Adams et al., 2001) . However, survivin also has functions characteristic of an IAP protein despite having only a single BIR domain and lacking a RING motif. It appears to associate with both caspases 3 and 9 at the microtubules and sequesters the proteases in an inactive state (Shin et al., 2001) . Dissociation of survivin from the microtubules causes activation of caspase 3 and overexpression of survivin reduces caspase 3 activity and counteracts apoptosis in endothelial cells (O'Connor et al., 2000; Shin et al., 2001) . Also, dominantnegative survivin mutants and antisense oligonucleotides have been used to disrupt endogenous survivin/ caspase association leading to caspase activation and apoptosis Chen et al., 2000) . Finally, there is evidence to suggest that survivin is critical in mediating PDGF-mediated vascular smooth muscle cell viability and that disruption of the survivin pathway with a dominant-negative mutant removes the protective effect of PDGF-AB following vascular injury (BlancBrude et al., 2002) .
Recently, a dominant-negative mutant, survivin T34A, has been shown to induce apoptosis in tumour models both in vitro and in vivo (Banks et al., 2000; Conway et al., 2000; Grossman et al., 2001; Mesri et al., 2001) . A single amino-acid substitution of Thr-34-Ala in the survivin protein prevents phosphorylation of Thr-34 by a cyclin-dependent kinase cdc2. This results in the dissociation of the survivin-caspase 9 complex at the microtubules allowing activation of the intrinsic apoptotic pathway (O'Connor et al., 2000) . It has since been postulated that survivin may also bind the second mitochondrial activator of caspases (Smac), a proapoptotic protein that binds IAPs thereby preventing inhibition of caspase activation Verhagen et al., 2000) . Chai et al. (2000) have shown a direct interaction between the N-terminal amino acids of processed Smac and the BIR3 domain of XIAP. It is possible that Smac interacts with the survivin BIR3 domain to cause survivin inhibition in the same way (Verdecia et al., 2000) .
In this study, we show that exogenous expression of procaspase 3 leads to upregulation of wild-type survivin expression at a transcriptional level in ovarian cancer cells, which may be a protective response to the proapoptotic effects of the caspase. We have utilized this finding to develop a combination gene therapy strategy for ovarian cancer. Firstly, we confirm that expression of survivin T34A is capable of inducing apoptosis in ovarian cancer cells. Other groups have previously used adenoviral constructs expressing caspase 3 as cancer therapies in vitro but concluded that transgene expression alone is insufficient to promote apoptosis without a second stimulus such as Fas-L (Shinoura et al., 2000) , etoposide (Yamabe et al., 1999) or promoter-specific induction of the active form of the protease (Shariat et al., 2001) . However, we show here that an adenovirus expressing procaspase 3 alone (Ad Caspase 3) is sufficient to kill ovarian cancer cells. Ad Caspase 3-mediated apoptosis can also be enhanced using dominant-negative mutant survivin T34A. These data suggest that a combination gene therapy strategy involving the terminal caspase 3 and inhibition of apoptosis inhibitors could be useful in effecting tumour cell death in ovarian cancer.
Results
Ovarian carcinoma cell lines compensate for overexpression of procaspase 3 by expressing high levels of survivin
We have previously generated IGROV1-caspase 3, ovarian carcinoma cells that stably overexpress both the 35 and 32 kDa isoforms of procaspase 3 following plasmid transfection and antibiotic selection (Figure 1a ) . It was also noted that expression of survivin was upregulated in IGROV1-caspase 3 cells compared to parental IGROV1 cells (Figure 1a ), despite having similar doubling times (see discussion: data not shown). This result suggests that one of the cellular responses to procaspase 3 expression is the upregulation of survivin and we postulated that downregulation of survivin activity could enhance the proapoptotic effect of caspase 3.
To test this hypothesis, we employed the dominantnegative mutant survivin T34A to reduce endogenous survivin activity. IGROV1 and IGROV1-caspase 3 cells were transfected with plasmids encoding survivin T34A, wild-type survivin or a control plasmid and then assayed for cell survival 72 h later (Figure 1b ). There was no significant reduction in cell survival following control plasmid or survivin wild-type transfection. However, in survivin T34A-transfected cells, there was a reduction in cell survival in both IGROV1 and IGROV1-caspase 3 cells (57.279.4% for IGROVI and 29.575.6% for IGROV-caspase 3 cells; mean7s.d., n ¼ 6), but the reduction was significantly greater in the procaspase 3 expressing cells (Po0.001). This confirmed that survivin T34A causes cell death in IGROV1 cells but also that overexpression of procaspase 3 significantly enhanced this effect.
As a result of our observations, we assessed these two transgenes when expressed from adenoviral vectors in the ovarian carcinoma cell lines IGROV1, SKOV3ip1 and A2780CP. In all the three cell lines, both Western (Table 1 ) data again indicated that expression of procaspase 3 caused survivin upregulation, in contrast to transfection with a control adenovirus at the same multiplicity of infection (moi). To assess further both the specificity of survivin upregulation and to assess whether the responses to Ad Caspase 3 transfection were tumour specific, we compared mRNA levels of survivin and XIAP in IGROV1 cells and HuBE normal primary human bronchial epithelia, with expression of PGK mRNA used an internal control. In IGROV1 cells transfected with Ad Caspase 3, survivin expression increased greatly, but XIAP remained relatively unchanged. In contrast, transfection of HuBE bronchial epithelia with Ad Caspase 3 at the same moi produced no change in either survivin or XIAP expression compared to baseline. This suggests that the upregulation of survivin in response to caspase 3 overexpression may be tumour specific and does not occur with other IAPs such as XIAP.
Apoptosis induced by Ad Survivin T34A proceeds via a caspase 9-and caspase 3-mediated pathway that is unaffected by G2/M cell cycle arrest
The function of caspase 3 in apoptosis is well characterized but the role of survivin and the process by which survivin T34A affects apoptosis are less well defined. Protein lysates from IGROV1 cells transfected with Ad Survivin T34A, Ad Caspase 3 and the empty vector Ad Control were analysed for the activation of caspases 3, 8 and 9 ( Figure 3a ). IGROV1 cells transfected with Ad Survivin T34A at an moi of 10 showed cleavage and activation of caspases 9 and 3 but not caspase 8. This is consistent with activation of the intrinsic apoptotic pathway thought to be inhibited by IAPs. Similarly, following Ad Caspase 3 transfection at the same moi, there is cleavage of procaspase 3 as well as some activation of caspase 9, whereas Ad Control transfection at the same moi did not induce cleavage of any of the caspases studied.
It has been suggested that downregulation of endogenous survivin may induce apoptosis by causing a cell cycle block during microtubule disassembly . To investigate if Ad Survivin T34A-induced apoptosis was cell-cycle-dependent, cells were arrested at G2/M prior to microtubule disassembly with nocodazole (Vasquez et al., 1997) and then transfected by Ad Survivin T34A (moi 10) or Ad Caspase 3 (moi 10) (Figure 3b ). At 18 h after nocodazole application, 81.4% IGROV1 cells were blocked in G2. In the absence of nocodazole, following Ad Survivin T34A and Ad Caspase 3 transfections, the percentage of IGROV1 cells in sub-G1, characteristic of apoptosis, were 44 and 82%, respectively. In IGROV1 cells treated with nocodazole, the figures were 46 and 80%, respectively. Ad Control-transfected cells showed no increase in sub-G1 population compared to untreated cells. Furthermore, there was no increase in the apoptotic population in those cells treated with nocodazole alone indicating that the drug does not induce apoptosis at this time. These data suggest that Ad Survivin T34A, like Ad Caspase 3, induces apoptosis independently of a G2/M block. We further confirmed by Western blot, that, even in mitotically inactive, nocodazole-treated cells, endogenous survivin is still upregulated following transfection with Ad Caspase 3 ( Figure 3c ).
Apoptosis is synergistically increased in ovarian cancer cells transfected with both Ad Survivin T34A and Ad Caspase 3
Having shown that Ad Survivin T34A causes apoptosis via a caspase 3-mediated pathway, we investigated ) were transfected with Ad Caspase 3 at an moi of either 5 or 10. The same number of untransfected cells were used as a standard control and cells transduced with Ad Survivin T34A (moi 10) were used as a positive control for survivin expression. At 48 h posttransfection, total RNA was extracted, cDNA reverse transcribed and survivin and XIAP transcript quantified by real-time PCR as described in Materials and methods. Experiments were performed in triplicate and results presented are mean7s.d. (Figure 4a ). There was no significant reduction in cell survival following treatment with Ad Control at the same moi. However, when Ad Survivin T34A and Ad Caspase 3 were combined 1 : 1 to give a total moi of 10 (i.e. moi 5+5), cell survival was only 31.274.1%, which is significantly less than either Ad Survivin T34A (Po0.001) or Ad Caspase 3 (Po0.001) alone. To investigate this further, we used annexin V/DAPI staining as markers for apoptosis/necrosis (Figure 4b ). IGROV1 cells were again exposed to Ad Survivin T34A (moi 10) or Ad Caspase 3 (moi 10) or both viruses together (moi 5 each). Again, there is a greater than additive increase in apoptotic cells following combination as compared to individual viral transfection, strongly suggesting true synergy between Ad Survivin T34A and Ad Caspase 3.
Survivin T34A and Caspase 3 coexpression shows therapeutic potential in vivo To investigate the potential therapeutic potential of the survivin T34A/caspase 3 combination in vivo, we injected 3 Â 10 6 IGROV1 cells intraperitoneally into female adult nude mice. After 3 days, mice were injected intraperitoneally with adenoviral constructs for three successive days. Mice were then assessed daily for weight, general health and accumulation of ascites. Animals were treated in groups of eight with Ad Control (5 Â 10 10 particles/day), Ad Survivin T34A (5 Â 10 10 particles/day), Ad Caspase3 (5 Â 10 10 particles/day), or a combination treatment of Ad Survivin T34A (1 Â 10 10 particles/day) plus Ad Caspase 3 (also 1 Â 10 10 particles/ day) and the survival curves are shown in Figure 5 . Treatment with Ad Survivin T34A did not extend survival significantly compared to Ad Control-treated animals (median survival 24 days for Ad Survivin T34A; 26.5 days for Ad Control), whereas treatment with Ad Caspase 3 did extend survival significantly (median survival 44.5 days, Po0.0001). However, the combination of Ad Survivin T34A and Ad Caspase 3 at low dose increased survival by the greatest amount (median survival 47 days, Po0.0001). In both the Ad Caspase 3 alone and the combination groups, there was one longterm survivor (>196 days) at the termination of the experiment.
Discussion
The dominant-negative mutant survivin T34A has previously been shown to induce apoptosis in a number of tumour cell lines but not in normal primary cells (Mesri et al., 2001) . Furthermore, it has been suggested that wild-type survivin inhibits apoptosis initiated via the intrinsic death pathway Shin et al., 2001) . We have previously produced an ovarian cancer cell line stably overexpressing procaspase 3 (IGROV1-Caspase 3), the effector caspase of the intrinsic apoptotic pathway. We found that overexpression of procaspase 3 alone did not induce apoptosis but caused elevated levels of survivin as compared to parental IGROV1 cells. Survivin is only normally expressed in adult cells at G2/M phase of the cell cycle Figure 3 Adenovirus expressing a dominant-negative survivin mutant induces apoptosis via a caspase 9/caspase 3-mediated pathway that is unaffected by G2/M cell cycle arrest. IGROV1 cells were transfected with Ad Survivin T34A, Ad Caspase 3 or Ad Control (moi 10 for all viruses) or were mock-infected. At 72 h post-transfection, cellular lysates were analysed for either survivin, caspase 3, 8 or 9 expression by Western blot (a). Also, IGROV1 cells were treated with 1 mm nocodazole 18 h prior to transfection with all the three viruses and then analysed for cell cycle status (b) or expression of survivin by Western blot (c) and, as both cell lines have the same doubling times, our findings suggested that elevated procaspase 3 expression is causing a concomitant upregulation of native survivin. There has been one recent report that Panc-1 pancreatic carcinoma cells increase transcription of survivin in response to cisplatin chemotherapy (Ikeguchi et al., 2002) and there is also evidence that rodent IAP-2 transcription increases in response to severe hypoxia (Dong et al., 2002) . Very recently, there has also been one report that MCF-7 and HeLa cells increase survivin expression in response to a variety of chemotherapy drugs, as well as UVB inrradation, although these changes did not involve modulation of survivin mRNA expression (Wall et al., 2003) .
Based on our initial observation, we postulated that downregulation of native survivin in the presence of caspase 3 overexpression could have therapeutic potential in ovarian cancer cells. We first tested this hypothesis by transfecting IGROV1-Caspase 3 and IGROV1 cells with a plasmid encoding survivin T34A and assaying for cell survival. There was significantly less cell survival in survivin T34A plasmid-transfected IGROV1-Caspase 3 cells than parental IGROV1 cells suggesting that our hypothesis may be correct. We then constructed replication-defective adenoviral vectors 10 particles) or a combination of Ad Survivin T34A and Ad caspase 3 (1 Â 10 10 particles each) were injected daily for three consecutive days. Mice were monitored daily for the formation of ascites Procaspase 3 expression increases survivin transcription TR McKay et al expressing human procaspase 3 (Ad Caspase 3) and survivin T34A (Ad Survivin T34A) under the control of a CMV promoter. In all the three ovarian cancer cell lines tested, we found that survivin was overexpressed when the cells were transfected with Ad Caspase 3. Survivin overexpression was not observed in cells transfected with an empty adenovirus at the same moi. To investigate this further and to explore whether the increase in survivin resulted from transcriptional activity, we compared the increase in mRNA of both survivin and another IAP, XIAP, by realtime PCR in both IGROV1 cells and HuBE normal primary human bronchial epithelia. We found that survivin, but not XIAP, was greatly upregulated in the IGROV1 cells following Ad Caspase 3, while in HuBE cells, neither survivin nor XIAP was upregulated, which suggests that manipulation of survivin function may be able to cause tumour-specific apoptosis.
Confirmation that Ad Survivin T34A caused apoptosis in IGROV1 cells by a caspase 9/caspase 3-mediated pathway was provided by Western blot analysis of transfected cells, which showed cleavage of caspases 9 and 3 but not caspase 8. This is characteristic of apoptosome formation and caspases 9 and 3 recruitment and activation following release of cyctochrome c from mitochondria, a pathway known to be inhibited by IAPs (Zou et al., 1999; Bratton et al., 2001) . Interestingly, we found that treatment of ovarian carcinoma cells with Ad Caspase 3 alone was able to induce apoptosis, in contrast to previous published data (Yamabe et al., 1999; Shinoura et al., 2000) and that the pattern of caspase activation was similar to that induced by Ad Survivin T34A. This suggests that when procaspase 3 is expressed from an adenoviral cassette, it can produce terminal caspase cleavage via an upstream mechanism involving caspase 9 whereas stably transfected procaspase 3 cannot. This may be the result of proapoptotic adenoviral proteins, such as E4orf4, triggering an apoptotic signal, although the precise mechanisms are yet to be fully elucidated (Lavoie et al., 1998; Livne et al., 2001) . Secondly, this may simply reflect the quantity of procaspase 3 expressed. It is known that caspase 3 has some autocatalytic activity (Nicholson, 1999) and it is possible that adenoviral transfection produces enough protein to breach a catalytic threshold resulting in a generalized apoptotic signal, while cells stably transfected with a plasmid cannot express such high levels of the caspase.
It has been suggested that survivin may act as a chromosomal passenger protein which, when inhibited, prevents microtubule disassembly at G2/M thereby initiating an apoptotic cascade (Li et al., 1998) . To investigate whether Ad Survivin T34A-mediated apoptosis was associated with G2/M, we first blocked IGROV1 cells upstream of microtubule disassembly with nocodazole and then transfected cells with Ad Survivin T34A and Ad Caspase 3. Ad Survivin T34A, like Ad Caspase 3, caused an increase in the sub-G1 population typical of apoptosis in both nocodazole-treated and untreated cells. This suggests strongly that survivin T34A does not rely on a G2/M block for its effect. Ad Caspase 3-transfected cells act as a positive control for cell-cycle-independent apoptosis. Furthermore, IGROV1 cells transfected with Ad Caspase 3 expressed elevated levels of survivin even when mitosis was blocked, suggesting that survivin expression is upregulated in response to increased levels of procaspase 3 and not to cell cycle phenomena.
In order to investigate combined therapy, we transfected IGROV1 cells with Ad Survivin T34A and Ad Caspase 3 at an moi of 10 of single virus or in combination at moi 5 each. Any extra apoptosis in the combination population would suggest that the two transgenes were working in synergy rather than purely additively. We found that at an moi of 10, considerable cell death was caused by transfection with either virus alone. However, together, we observed a greater than additive effect in annexin V positive cells, even though only half as much of each virus was added. We conclude that the two transgenes may be acting in true synergy in IGROV1 ovarian carcinoma cells. From our data, it appears probable that the expression of both transgenes, even at comparatively low levels is sufficient to trigger a terminal apoptotic cascade in vitro. Furthermore, we have shown preliminary in vivo evidence of a therapeutic effect of survivin T34A with caspase 3 expression. Mice were implanted with IGROV1 cells intraperitoneally and then 3 days later subjected to three daily intraperitoneal applications of virus. Mice transfected with 5 Â 10 10 particles/day of Ad Survivin T34A showed no significant increase in survival compared to mice treated with a control virus. However, mice treated with 5 Â 10 10 particles/day of Ad Caspase 3 showed a significant increase in survival, confirming our in vitro data where Ad Caspase 3 alone was able to induce apoptosis in IGROV1 cells. A combination of both viruses resulted in a significant increase in survival from Ad Control-treated animals also but was not significantly greater than Ad Caspase 3 alone. However, it must be noted that the total viral dose applied in the combined group (2 Â 10 10 particles/ day for 3 days) was less than half the number of viral particles than with Ad Caspase 3 alone (5 Â 10 10 particles/day for 3 days) indicating that a degree of synergy may also exist between these two transgenes in vivo. There was also one long-term survivor (>196 days) in both the Ad Caspase 3 group and the combination group, suggesting that this gene therapy strategy may be able to produce complete cures in this model of ovarian carcinoma.
We conclude that ovarian cancer cells that overexpress procaspase 3 compensate by expressing elevated levels of survivin. A dominant-negative mutant survivin, T34A, is able to promote cleavage of terminal procaspase 3 by pushing the apoptotic equilibrium in favour of cell death and we have shown data that Ad Survivin T34A and Ad Caspase 3 can increase survival in a murine ovarian xenograft model. Therefore we predict that efficient inhibition of IAPs in conjunction with overexpression of a terminal caspase may have major therapeutic benefit in ovarian cancer.
Materials and methods

Maintenance of cells in culture
The ovarian carcinoma cell lines IGROV1 (donated by Dr M Ford, Glaxo-SmithKline, Stevenage, UK) and SKOV3ip1 (donated by Dr J Price, MD Anderson Cancer Center, Houston, TX, USA) were maintained in DME medium, A2780CP cells (donated by Dr A Eliopoulous, University of Birmingham, UK) were maintained in RPMI medium, both supplemented with 10% foetal calf serum (FCS) (Autogen Bioclear, UK) and 50 mg/ml penicillin and 50 mg/ml streptomycin (Life Technologies, Gaithersburg, MD, USA). IGROV1 cells stably expressing procaspase 3 were maintained in medium supplemented with 1 mg/ml G-418 (Life Technologies, Gaithersburg, MD, USA). 293 cells used for adenoviral amplification were maintained in DME medium supplemented with 10% FCS and 50 mg/ml penicillin/streptomycin. HuBE cells are normal human bronchial epithelial cells (obtained from BioWhittaker Clonetics, San Diego, CA, USA) and were maintained in epithelial basal medium supplemented with bovine pituitary extract, EGF, hydrocortisone, adrenaline, transferrin, insulin, retinoic acid, tri-iodothyronine, gentamicin and amphotericin-B, according to the supplier's instructions. All cells were grown and maintained at 371C in 10% CO 2 .
Plasmid transfection In Vitro
Cells were seeded at 5 Â 10 5 cells per well in six-well plates 24 h prior to transfection. In each case, 5 mg of plasmid DNA was added to 40 mg polyethylenimine (25 kDa polymer; Sigma-Aldrich, Poole, UK) per well in a total of 200 ml serum-free medium and incubated at room temperature for 20 min. Cells were washed three times in serumfree medium and then the transfection solution was added to the cells in a total of 1 ml medium and incubated at 371C, 5% CO 2 for 4 h. Cells were re-fed with DMEM plus 10% FCS and further incubated for 72 h when cells were assayed for survival.
Construction of recombinant adenoviral vectors
The survivin T34A dominant-negative mutant was produced by RT-PCR amplification of survivin cDNA as previously described by Zhao et al. (2000) and subsequent PCR mutagenesis using the primers 5 0 -gagggctgcgcctgcgccccggagcggatggcc-3 0 and 5 0 -ggccatccgctccggggcgcaggcgcagccctc-3 0 . The resultant survivin mutant was sequenced before subcloning into the adenoviral plasmid pAdTrack CMV. A recombinant adenoviral construct containing dominant-negative mutant survivin T34A (Ad Survivin T34A) under the control of a CMV promoter in the E1 region was produced using the Ad Easy bacterial recombination system (www.coloncancer.org/adeasy.htm) as outlined by He et al. (1998) . The procaspase 3 cDNA sequence was reverse transcribed and PCR-amplified from total RNA extracted from OVCAR3 cells and cloned into pNRTIS-33 as previously described . The procaspase3 cDNA was subsequently cloned into pAdTrack CMV as a Kpnl/Xhol fragment. Ad Control is a replication-incompetent adenoviral vector in which the E1 region is replaced by a 1.4 kb Sal1 fragment containing the À1406/+33 MUC1 promoter with no transgene (Kovarik et al., 1993) . The integrity of the Ad Easy adenoviral constructs was confirmed by restriction analysis with Pacl and HindIII digests subjected to electrophoresis on 1% agarose gels under pulsed field. Adenoviral particles were produced by amplification on 293 cells and subsequent purification by double-density CsCI gradient ultracentrifugation.
Adenoviral transfection In Vitro
Cells were plated into either six-well or 24-well dishes at 1 Â 10 5 cells/cm 2 18 h prior to transfection. Adenovirus was diluted in growth medium to give a final volume of 200 ml per well of a 24-well plate or 500 ml per well of a six-well plate. The viral transfection solution was added overnight and then removed and the cells re-fed with growth medium. Cells were incubated at 371C/10% CO 2 for 72 h and then assayed for viability or apoptosis. For nocodazole treatment, cells were plated out 18 h prior to addition of 1 mm nocodazole to the growth medium. After 18 h, cells were transfected with adenoviral vectors in the presence of fresh nocodazole, refeeding with nocodazole-containing growth medium every 24 h until final assay.
Cell survival and apoptosis analyses
Cell survival assays were carried out using the MTT (3[4,5-dimethylthiazol-2-y]-2-5-diphenyltetrazolium bromide; SigmaAldrich, Poole, UK) assay. For flow cytometry, >10 6 cells were trypsinized, washed three times in PBS and fixed in ice-cold 70% ethanol. Cells were then washed twice with phosphate citrate buffer (192 mm Na 2 HPO 4 , 40 mm citric acid), treated with RNase A and stained with propidium iodide. Cell cycle status was analysed using a FACS calibur flow cytometer (Becton Dickinson). For annexin V staining, cells were harvested and resuspended in 1 ml HEPES buffer (10 mm HEPES, 140 mm NaCl, 2.5 mm CaCl 2 ). Annexin V-Alexa647 (Molecular Probes Europe, Leiden, Netherlands) was added according to the manufacturer's recommendation followed by incubation in the dark at room temperature for 30 min. DAPI was added prior to analysis to allow gating of dead cells. Ad Caspase 3 and Ad Survivin T34A both contain the GFP gene under the control of a second CMV promoter and transfected cells were also analysed for green fluorescence.
Semiquantitative real-time PCR
Cells were seeded in six-well plates at 5 Â 10 5 cells per well and transfected with adenoviral constructs. After 48 h, total RNA was extracted using RNAzol B (Biogenesis, Poole, UK). The RNA was subjected to DNase treatment prior to final column purification using the RNEasy RNA purification kit (Qiagen, Crawley, West Sussex, UK). First-strand cDNA was reverse transcribed from the total RNA using the First-Strand cDNA synthesis kit (Roche Pharmaceuticals, Indianapolis, IN, USA) utilizing random hexamer nucleotides for initiation priming. A volume of 1 ml (100 ng) of cDNA was used in realtime PCR reactions using an ABI Prism 7700 PCR machine. Primers used were as follows: Survivin (F): 5 0 -cccatagaggaacataaaaagcattc-3 0 , (R): 5 0 -tcaaaaattcaccaagggttaattct-3 0 ; XIAP (F): 5 0 -gacagtatgcaagatgagtcaagtca -3 0 , (R): 5 0 -caaagcttctcctcttgcag-3 0 ; PGK (F): 5 0 -tggagaacctccgctttcat-3 0 and (R): 5 0 -tggctcggctttaaccttgt-3 0 . Data were analysed using the ABI Prism 7700 SDS applications F software and associated data analysis package.
Protein analysis by Western blot
Transfected cells were trypsinized, pelleted and suspended in lysis buffer (150 mm NaCl, 50 mm Tris pH 7.5, 0.05% SDS, 1% Triton X-100). The cell suspension was then subjected to three rounds of sonication at 20 mm using an MSE Soniprep for 5 s each. Samples were heat denatured at 951C for 3 min and then electrophoresed at 3 V/cm 2 for 45-60 min on 12% SDS-PAGE gels. Protein was transferred to Hybond ECL nitrocellulose membrane (Amersham Pharmacia Biotech, Bucks, UK) by semidry electroblotting. Membranes were blocked in either 1.5% BSA (for caspase 3 or caspase 9 immunoblots) or 5% nonfat milk powder (for survivin or caspase 8 immunoblots), after which primary antibody was added for 1 h at room temperature (rabbit anticaspase 3 polyclonal antibody was supplied by BD PharMingen Europe, Oxford, UK; mouse anti-caspase 8 monoclonal antibody and antiserum (purified) to activated caspase 9 were both supplied by Alexis Biochemicals, Nottingham, UK; rabbit anti-human survivin antibody was supplied by R&D Systems, Minneapolis, MN, USA). Antibody binding was detected by enhanced chemiluminescense using ECL (Amersham Pharmacia Biotech, Bucks, UK) and X-OMAT autoradiograph film (Kodak, UK).
In Vivo analyses 3 Â 10 6 IGROV1 cells were injected intraperitoneally into adult female nude mice on day 1. Commencing on day 4, the mice were injected intraperitoneally with Ad Control, Ad Survivin T34A or Ad Caspase 3 daily for three consecutive days. Mice were then assessed daily for weight, general health and accumulation of ascites. When animals were judged to be terminally sick, they were killed, tumours were dissected and weighed and ascites volume measured. A full pathological assessment was made for each animal.
